| pubmed-article:10602023 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0205147 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0024432 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0019721 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0596988 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0961954 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C1100939 | lld:lifeskim |
| pubmed-article:10602023 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:10602023 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10602023 | pubmed:dateCreated | 2000-1-24 | lld:pubmed |
| pubmed-article:10602023 | pubmed:abstractText | Human macrophage and T cell lines were stably transfected with HIV-1 wild-type Tat or Tat mutants in the cysteine-rich region displaying trans-dominant negative effects on HIV-1 life cycle. The expression of HLA class I and class II molecules was not affected by wild-type Tat. Tat mutants, instead, profoundly down-regulated in a dose-dependent fashion the expression of class II, but not of class I, in both cell types by acting at the transcriptional level. Down-regulation was manifested on constitutive and IFN-gamma-induced class II gene expression and did not correlate with reduced transcription of the AIR-1 gene product CIITA, the major transcriptional activator of class II genes, indicating that Tat mutants did not act by inhibiting AIR-1 gene expression. Class II down-modulation had important functional implications in macrophages, as both antigen processing and presenting capacity were inhibited. These results represent the first evidence that a modified HIV-1 Tat product can act as a potent immunosuppressor by inhibiting the HLA class II expression necessary for triggering both cellular and humoral responses against pathogens. The use of these HIV-1 Tat mutants also discloses new opportunities to investigate the molecular mechanisms underlying the coordinate HLA class II gene transcription. | lld:pubmed |
| pubmed-article:10602023 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10602023 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10602023 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10602023 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10602023 | pubmed:issn | 0014-2980 | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:Barbanti-Brod... | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:CaputoAA | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:MancaFF | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:AccollaR SRS | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:ValleM TMT | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:D'AgostinoAA | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:TosoAA | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:De Lerma... | lld:pubmed |
| pubmed-article:10602023 | pubmed:author | pubmed-author:MegiovanniA... | lld:pubmed |
| pubmed-article:10602023 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10602023 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:10602023 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10602023 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10602023 | pubmed:pagination | 19-28 | lld:pubmed |
| pubmed-article:10602023 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:meshHeading | pubmed-meshheading:10602023... | lld:pubmed |
| pubmed-article:10602023 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10602023 | pubmed:articleTitle | HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines. | lld:pubmed |
| pubmed-article:10602023 | pubmed:affiliation | Department of Clinical and Biological Sciences School of Medicine, University of Insubria, Varese, Italy. | lld:pubmed |
| pubmed-article:10602023 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10602023 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10602023 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10602023 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10602023 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10602023 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10602023 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10602023 | lld:pubmed |
